Hims & Hers Health, Inc. (HIMS) Q1 2025 Earnings Call Transcript
Hims & Hers Health, Inc. (NYSE:HIMS ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Bill Newby - Head of Investor Relations Andrew Dudum - Co-Founder and Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Maria Ripps - Canaccord Genuity Eric Percher - Nephron Research Ryan MacDonald - Needham Daniel Grosslight - Citi George Hill - Deutsche Bank David Larsen - BTIG Aaron Kessler - Seaport Research Operator Good afternoon, ladies and gentlemen. Thank you for standing by.
Here's What Key Metrics Tell Us About Hims & Hers Health (HIMS) Q1 Earnings
While the top- and bottom-line numbers for Hims & Hers Health (HIMS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Hims & Hers Health, Inc. (HIMS) Beats Q1 Earnings and Revenue Estimates
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.05 per share a year ago.
Hims & Hers (HIMS) Blows Out Earnings Expectations
Hims & Hers Health, Inc. reported a strong financial performance for Q1 2025, with revenue reaching $586 million, marking a 111% increase year-over-year.
Hims & Hers Health Revenue Jumps, But Outlook Disappoints
Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook missed Wall Street's expectations.
EARNINGS ALERT: HIMS
While Palantir (PLTR) trading was vastly unchanged after hours , Hims & Hers (HIMS) saw some downside action following its earnings. George Tsilis notes it has "become quite profitable over the years," attributing part of the sell-off to the telehealth company's valuation.
Can Sustained Product Demand Drive HIMS Stock Before Q1 Earnings?
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the first quarter of 2025.
Hims & Hers: Revolutionizing Healthcare
The company's vertically integrated platform enhances scalability and efficiency, controlling the entire patient experience from consultation to medication delivery. Partnerships, especially with Novo Nordisk for GLP-1 weight-loss drugs, significantly boost revenue and deepen customer relationships. Embracing AI and peptide therapies positions Hims & Hers for future growth, though regulatory compliance and reliance on third-party suppliers pose risks.
Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?
Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
Hims & Hers vs. Teladoc: Which Telehealth Stock Is the Better Buy Now?
Both HIMS and TDOC are technology-intensive healthcare companies that leverage their strengths in the digital health space to enhance their platforms. Which one is a better investment?
Hims & Hers Stock Soars on Novo Nordisk Collaboration
Every once in a while, investors come across some of the best names in a given industry, which then become subject to the best news and developments during a holding period. Today's best pick seems to be in the medical sector.
Hims & Hers stock price soars after partnership with Novo Nordisk to offer weight-loss drug Wegovy
Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordisk. That partnership will see Hims & Hers offer Novo Nordisk's weight-loss drug Wegovy through its platform.
